Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

IVD Medical
華檢醫療 (1931.HK)

Innovation . Verification . Development

IVD Medical Holding Limited
華檢醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1931)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION WITH BGI CO-WIN

This announcement is made by IVD Medical Holding Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with the latest information on recent developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on 30 July 2025, the Company entered into a strategic cooperation framework agreement (the "**Framework Agreement**") with BGI Co-Win (Shenzhen) Equity Investment Fund Management Co., Ltd. ("**BGI Co-Win**") in relation to the joint establishment of the IVD-BGI Co-Win Innovatve Drug Intellectual Property Tokenization Fund (IVD-BGI CoWin) (the "**Fund**") in Hong Kong/the United States or other overseas regions to invest in projects under the NewCo + RWA Web3 Exchange Ecosystem operating model of the Company (the "**Strategic Cooperation**").

Pursuant to the Framework Agreement, the Company or its designated entity will contribute to the Fund as a limited partner, and BGI Co-Win or its designated entity will be responsible for the operation and management of the RWA Fund of the medical innovative drug NewCo as a general partner. At the request of the Company, BGI Co-Win will screen high-quality innovative pharmaceutical companies or target assets (the "**Target Projects**") in the fields of innovative medical and medical innovative drug, both domestically and internationally, that align with the Company's strategic needs and provide the Company with services such as the promotion of the Target Projects, special due diligence, financing coordination, and design of the transaction plans.

BGI Co-Win is a private equity fund manager registered with the Asset Management Association of China, and operates as a Corporate Venture Capital (CVC) entity initiated by biotechnology leader, BGI, with years of domestic and international investment experience and project resources in the fields of innovative medical and medical innovative drug.

The Board believes that the Strategic Cooperation will advance the Company's objective of expanding its business layout through the three-pronged strategy of "NewCo + RWA + Stablecoin" and reinforcing its role in reshaping the global value chain of medical innovative drug assets. Accordingly, the Board considers that the entering into of the Framework Agreement is in the interests of the Company and its shareholders as a whole.

The Board wishes to emphasize that the Strategic Cooperation may or may not proceed. The Framework Agreement is a framework agreement for strategic cooperation and specific matters involved in such cooperation shall be further defined by the parties upon the execution of corresponding agreements in subsequent cooperation. If the transactions contemplated under the Framework Agreement materialize, the Company will make further announcement(s) as and when appropriate in accordance with The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 30 July 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements are not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.

If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.